→ With just a few more days before he officially becomes Novartis’ new CEO, Vas Narasimhan is joining the world’s power circle. Case in point: Narasimhan joined a group of big-time European CEOs who sat down with President Donald Trump for dinner at Davos.
→ Two IPOs pitched at a year-end blitz have materialized. Focusing on elderly respiratory tract infections, resTORbio has raised $85 million by offering 5.7 million shares at $15. The Cambridge, MA biotech plans to list as $TORC, a tribute to the mTORC1 inhibitors its founders believe have potential to treat a variety of aging-related ailments. Then there’s I/O player Armo Biosciences, which went above its original $86 million for 6.7 million shares plan and bagged $128 million instead with an offering of 7.5 million shares at $17. It will go on Nasdaq as $ARMO.
→ Following ertugliflozin’s approval in the US, an EMA panel recommendation today sets Merck $MRK and Pfizer $PFE on the path for a European green light. The diabetes drug, marketed as Steglatro, will have some tough competition in the SGLT2 inhibitor class with products from Eli Lilly, J&J and AstraZeneca. With Sanofi/Lexicon ready to join the party, all eyes are on the upcoming cardio data, which will likely determine the winners.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 29,000+ biopharma pros who read Endpoints News by email every day.Free Subscription